Markets:

Overview

News

Currencies

International

Treasuries

Lakewood-Amedex Biotherapeutics Inc. - Common Stock (NQ:LABT)

0.7822 +0.0022 (+0.28%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Lakewood-Amedex Biotherapeutics Inc. - Common Stock

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

October 07, 2026

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) today announced positive preclinical data in urinary tract infection (UTI) and pulmonary infection indications in animal models treated with...

Via B2i Digital

Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape

October 07, 2026

From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of...

Via FinancialNewsMedia

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

October 01, 2026

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.

Via B2i Digital

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

September 28, 2026

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced positive Minimum Inhibitory Concentration (MIC) data from recent clinical isolates for its lead clinical candidate, Nu-3.

Via B2i Digital

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

September 24, 2026

Lakewood-Amedex Biotherapeutics Inc. today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating Nu-3 for the treatment of patients with mildly infected diabetic...

Via B2i Digital

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

September 21, 2026

Lakewood-Amedex Biotherapeutics Inc. today announced that Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics, has issued a Letter to Shareholders highlighting the...

Via B2i Digital

Topics Intellectual Property

Lakewood-Amedex announces IRB approval and clinical site readiness for the Phase 2a trial of Nu-3

September 18, 2026

Lakewood-Amedex received IRB approvals and confirmed site readiness to begin its Phase 2a trial of Nu-3 for iDFU.

Via B2i Digital

Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

August 25, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Derivatives

Tech Stocks LABT, ANY, INLF, GMGMF, ZCMD Under $2 Watch Now

July 23, 2026

Via AB Newswire

Topics Artificial Intelligence

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

June 26, 2026

From Virtual Investor Conferences

Via GlobeNewswire

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

June 23, 2026

Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.